Claims for Patent: 12,336,971

Summary for Patent: 12,336,971

Title:	Ophthalmic pharmaceutical compositions and uses thereof
Abstract:	Provided herein are ophthalmic pharmaceutical compositions comprising (1R,2S,5R)-2-isopropyl-N-(4-methoxyphenyl)-5-methylcyclohexane-1-carboxamide (WS-12) for effectively treating dry eye in a subject in need thereof, effectively reducing dry eye in a subject in need thereof, effectively reducing the likelihood of dry eye in a subject in need thereof, or for treating, preventing, or ameliorating signs or symptoms of dry eye in a subject in need thereof.
Inventor(s):	Anjali Joshi
Assignee:	Alcon Inc
Application Number:	US18/510,437
Patent Claims:	1. A method of treating dry eye or reducing the likelihood of dry eye in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a liquid ophthalmic pharmaceutical composition, wherein the liquid ophthalmic pharmaceutical composition comprises a viscosity of less than 5 cP, and the liquid ophthalmic pharmaceutical composition comprises: about 0.003% w/v (1R,2S,5R)-2-isopropyl-N-(4-methoxyphenyl)-5-methylcyclohexane-1-carboxamide; about 0.14% w/v hypromellose; about 3.0% w/v polyoxyl 35 castor oil; about 0.78% w/v sodium dihydrogen phosphate dihydrate buffer; about 0.55% w/v NaCl; a pH of about 7; and water. 2. A method of treating an ophthalmic disease or disorder involving tear production or reducing the signs or symptoms of the ophthalmic disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a liquid ophthalmic pharmaceutical composition, wherein the liquid ophthalmic pharmaceutical composition comprises a viscosity of less than 5 cP, and the liquid ophthalmic pharmaceutical composition comprises: about 0.003% w/v (1R,2S,5R)-2-isopropyl-N-(4-methoxyphenyl)-5-methylcyclohexane-1-carboxamide; about 0.14% w/v hypromellose; about 3.0% w/v polyoxyl 35 castor oil; about 0.78% w/v sodium dihydrogen phosphate dihydrate buffer; about 0.55% w/v NaCl; a pH of about 7; and water. 3. A method of treating dry eye or reducing the likelihood of dry eye in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a liquid ophthalmic pharmaceutical composition, wherein the liquid ophthalmic pharmaceutical composition comprises a viscosity of less than 5 cP, and the liquid ophthalmic pharmaceutical composition comprises: about 0.0014% w/v (1R,2S,5R)-2-isopropyl-N-(4-methoxyphenyl)-5-methylcyclohexane-1-carboxamide; about 0.14% w/v hypromellose; about 3.0% w/v polyoxyl 35 castor oil; about 0.78% w/v sodium dihydrogen phosphate dihydrate buffer; about 0.55% w/v NaCl; a pH of about 7; and water. 4. A method of treating an ophthalmic disease or disorder involving tear production or reducing the signs or symptoms of the ophthalmic disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a liquid ophthalmic pharmaceutical composition, wherein the liquid ophthalmic pharmaceutical composition comprises a viscosity of less than 5 cP, and the liquid ophthalmic pharmaceutical composition comprises: about 0.0014% w/v (1R,2S,5R)-2-isopropyl-N-(4-methoxyphenyl)-5-methylcyclohexane-1-carboxamide; about 0.14% w/v hypromellose; about 3.0% w/v polyoxyl 35 castor oil; about 0.78% w/v sodium dihydrogen phosphate dihydrate buffer; about 0.55% w/v NaCl; a pH of about 7; and water.